Specialty diagnostics companies continue to operate in a dynamic healthcare environment influenced by advances in molecular testing, precision medicine and demand for more specialized diagnostic solutions. Against this backdrop, Precipio, Inc. (PRPO Quick QuotePRPO - Free Report) and Fulgent Genetics, Inc. (FLGT Quick QuoteFLGT - Free Report) are two companies operating across diagnostic testing and related healthcare services. PRPO focuses on improving cancer diagnostics through a combination of clinical laboratory services and proprietary diagnostic products, with its pathology services centered primarily on hematologic cancers. Fulgent Genetics, meanwhile, provides a broad range of laboratory and genetic testing services, including anatomic pathology, precision diagnostics and specialized oncology testing, while also maintaining a therapeutic development business.

While both companies operate in advanced diagnostics and have exposure to oncology, they differ in their overall business scope, market presence and financial profile. These differences shape their competitive positioning and investment characteristics. This raises an important question: which stock is better positioned for investors today? Let’s take a closer look.

Stock Performance & Valuation: PRPO vs. FLGT

PRPO (up 15.5%) has underperformed FLGT (up 18.5%) over the past three months. However, in the past year, Precipio has gained 49% against Fulgent Genetics’ decline of 1.8%.

Image Source: Zacks Investment Research

Meanwhile, PRPO is trading at a trailing 12-month enterprise value-to-sales (EV/S) ratio of 1.66X, above its median of 1.23X over the past five years. FLGT’s trailing 12-month EV/S multiple sits at 1.04X, below its last five-year median of 1.13X. PRPO and FLGT both appear to be cheap when compared with the Zacks Medical sector average of 2.84X.

Image Source: Zacks Investment Research

Factors Driving Precipio Stock

Precipio’s product business is benefiting from a broader commercial push, supported by an expanded sales effort and deeper engagement with major distribution partners. Management indicated that the company is building a larger base of qualified prospects and working to move those opportunities into active customer accounts. This improves the potential for product sales to become a more meaningful and scalable contributor alongside the pathology business.

PRPO’s laboratory operations give its product-development efforts a differentiated foundation. The company can identify diagnostic challenges through routine clinical work, develop solutions internally and validate them using real patient specimens and clinician feedback. This approach can reduce reliance on stand-alone research infrastructure, lower development costs and shorten the path from concept to a clinically relevant product.

Precipio appears to be gaining better leverage from the infrastructure it has already built across laboratories, products and commercial operations. As revenue grows on this existing platform, a greater portion of incremental sales can potentially flow through to profitability and cash generation. Recent operating performance also showed that the business can generate cash internally, reducing dependence on external financing to support growth.

Factors Aiding Fulgent Genetics Stock

Fulgent Genetics is broadening its laboratory-services platform through the integration of Bako Diagnostics and StrataDx. The acquisitions strengthen its pathology capabilities, extend its laboratory and client footprint and create additional cross-selling opportunities. Cross-training across the combined commercial organization is also helping FLGT introduce a wider range of anatomic pathology services to existing customer relationships and build a broader opportunity pipeline.

Fulgent Genetics continues to invest in proprietary AI and digital pathology technologies aimed at improving laboratory efficiency and diagnostic consistency. Its expanding AI portfolio is designed to automate complex pathology tasks that traditionally require significant manual analysis. Beyond workflow improvements, these capabilities can support more advanced biomarker analysis and broaden the usefulness of FLGT’s digital pathology platform for clinicians, pharmaceutical companies and healthcare systems.

Fulgent Genetics’ therapeutic-development business provides a separate growth avenue beyond diagnostic services. Its lead oncology candidate has produced encouraging clinical findings and is moving toward further regulatory and late-stage development discussions, while another cancer candidate continues progressing through dose escalation. Both rely on the company’s proprietary CleanChemo platform, potentially allowing FLGT to apply the same underlying technology across multiple oncology programs.

Choose FLGT Over PRPO Now

Both Precipio and Fulgent Genetics have credible growth drivers, but their investment cases differ in breadth and valuation. PRPO is gaining traction in the commercialization of its proprietary diagnostic products, while its pathology operations support product development, validation and recurring service revenue. Its improving ability to generate cash internally also strengthens the model by reducing reliance on external funding.

FLGT, however, offers a more diversified growth platform. The integration of Bako Diagnostics and StrataDx is expanding its pathology capabilities and commercial reach, while investments in AI and digital pathology are improving workflow efficiency and diagnostic consistency. Its therapeutic pipeline adds another potential growth avenue beyond laboratory services, with both lead oncology programs continuing to advance clinically.

From a valuation standpoint, FLGT currently appears more reasonably priced relative to its own historical levels. Precipio trades above its five-year median, whereas Fulgent Genetics trades below its corresponding historical benchmark. Both stocks, however, remain valued below the broader sector average. This suggests that FLGT’s current valuation leaves more room for investor expectations to improve if its growth initiatives gain traction, while PRPO’s valuation already reflects some of its recent fundamental progress.

Considering FLGT’s broader diagnostics platform, acquisition-driven expansion, AI capabilities, therapeutic optionality and less demanding valuation, Fulgent Genetics appears to offer more upside at present. Precipio’s improving fundamentals remain encouraging, but its valuation already reflects more of that progress.